Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 31  •  04:00PM ET
3.39
Dollar change
+0.04
Percentage change
1.19
%
Index- P/E- EPS (ttm)-5.37 Insider Own40.84% Shs Outstand12.84M Perf Week2.11%
Market Cap45.87M Forward P/E- EPS next Y-3.50 Insider Trans-7.35% Shs Float8.00M Perf Month21.07%
Enterprise Value-36.68M PEG- EPS next Q-1.20 Inst Own50.91% Short Float0.81% Perf Quarter56.58%
Income-70.20M P/S- EPS this Y70.08% Inst Trans-29.83% Short Ratio0.59 Perf Half Y35.60%
Sales0.00M P/B0.59 EPS next Y23.50% ROA-85.20% Short Interest0.07M Perf YTD-60.58%
Book/sh5.78 P/C0.55 EPS next 5Y40.91% ROE-90.56% 52W High17.76 -80.91% Perf Year-81.03%
Cash/sh6.16 P/FCF- EPS past 3/5Y43.53% 4.41% ROIC-89.50% 52W Low1.70 99.41% Perf 3Y-88.89%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.11% 9.91% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM68.13% Oper. Margin- ATR (14)0.26 Perf 10Y-
Dividend Ex-Date- Quick Ratio11.13 Sales Y/Y TTM- Profit Margin- RSI (14)61.87 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio11.13 EPS Q/Q28.98% SMA2010.44% Beta0.46 Target Price30.00
Payout- Debt/Eq0.01 Sales Q/Q- SMA5020.76% Rel Volume0.62 Prev Close3.35
Employees46 LT Debt/Eq0.00 EarningsAug 12 AMC SMA2002.91% Avg Volume110.52K Price3.39
IPOApr 09, 2021 Option/ShortNo / Yes EPS/Sales Surpr.8.65% - Trades Volume68,378 Change1.19%
Date Action Analyst Rating Change Price Target Change
Apr-30-25Initiated Evercore ISI Outperform
Dec-05-24Initiated Leerink Partners Outperform $33
Oct-10-24Initiated Oppenheimer Outperform $35
Dec-15-23Downgrade Leerink Partners Outperform → Market Perform
Dec-15-23Downgrade Jefferies Buy → Hold
Dec-15-23Downgrade H.C. Wainwright Buy → Neutral $30 → $1.50
Dec-14-23Downgrade William Blair Outperform → Mkt Perform
Dec-14-23Downgrade Robert W. Baird Outperform → Neutral $28 → $3
Dec-14-23Downgrade Piper Sandler Overweight → Neutral $25 → $4
Dec-14-23Downgrade Ladenburg Thalmann Buy → Neutral
Aug-12-25 04:05PM
May-06-25 07:30AM
Mar-10-25 04:05PM
Mar-04-25 08:00AM
Dec-10-24 07:00AM
05:31PM Loading…
Nov-25-24 05:31PM
Nov-05-24 04:05PM
Nov-01-24 05:30PM
Oct-07-24 04:32AM
Oct-04-24 04:57PM
Oct-02-24 08:20PM
Aug-13-24 07:35AM
May-16-24 10:01AM
May-13-24 08:25AM
07:35AM
01:53PM Loading…
May-07-24 01:53PM
07:35AM
Mar-28-24 12:53PM
07:35AM
Mar-25-24 07:00AM
Dec-21-23 04:13PM
Dec-15-23 10:19AM
Dec-14-23 12:35PM
09:05AM
Nov-13-23 05:04PM
07:35AM
Nov-02-23 07:50AM
Oct-25-23 07:50AM
Oct-20-23 01:22PM
Oct-09-23 07:50AM
08:30AM Loading…
Oct-06-23 08:30AM
Aug-29-23 07:35AM
Aug-10-23 07:35AM
07:31AM
Jul-27-23 11:19AM
Jun-30-23 08:25AM
Jun-26-23 08:25AM
Jun-15-23 12:44PM
May-31-23 10:38AM
08:00AM
May-21-23 07:42PM
May-12-23 06:00PM
May-11-23 07:45AM
May-03-23 11:36PM
04:01PM
Mar-27-23 07:30AM
Mar-14-23 07:30AM
Mar-09-23 08:00AM
Mar-03-23 06:07AM
Feb-02-23 07:35AM
Jan-31-23 07:35AM
Dec-04-22 07:12AM
Nov-08-22 07:35AM
Nov-03-22 08:00AM
Sep-14-22 06:02AM
Sep-06-22 08:35AM
Aug-29-22 07:35AM
Aug-09-22 08:00AM
Aug-04-22 09:10AM
Aug-02-22 07:30AM
Jul-26-22 09:52AM
07:30AM
Jul-11-22 08:00AM
Jun-30-22 08:00AM
Jun-20-22 08:33AM
May-10-22 04:05PM
Mar-23-22 04:05PM
Mar-07-22 08:30AM
Feb-02-22 08:00AM
Jan-24-22 08:00AM
Jan-10-22 11:55AM
Dec-22-21 11:04AM
Nov-11-21 04:05PM
Nov-01-21 04:05PM
Oct-14-21 08:00AM
Oct-11-21 02:35PM
08:00AM
Sep-28-21 08:26AM
Sep-09-21 09:12AM
Aug-11-21 05:55AM
Jul-28-21 08:00AM
Jul-12-21 09:30AM
Jul-09-21 08:00AM
Jul-07-21 08:00AM
Jun-29-21 08:00AM
May-20-21 06:00AM
May-19-21 06:00AM
Apr-13-21 08:14AM
Apr-09-21 12:32PM
Apr-08-21 09:42PM
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Saccomano Nicholas APresident and CEOSep 22 '25Sale2.62882313,506Sep 24 07:42 PM
Leverone Jason A.Chief Financial OfficerSep 22 '25Sale2.6230379512,603Sep 24 07:41 PM
Saccomano Nicholas APresident and CEOJun 23 '25Sale2.38882103,594Jun 25 06:52 PM
Leverone Jason A.Chief Financial OfficerJun 23 '25Sale2.3830372212,906Jun 25 06:49 PM
Cormorant Asset Management, LPFormer 10% OwnerMay 15 '25Sale1.851,813,4393,363,0230May 19 05:33 PM
ACORN BIOVENTURES, L.P.10% OwnerMay 15 '25Buy1.851,129,7302,090,0001,129,730May 19 04:43 PM
ACORN BIOVENTURES, L.P.10% OwnerMay 15 '25Buy1.85270,270500,0001,709,944May 19 04:43 PM
Cormorant Asset Management, LP10% OwnerMay 12 '25Sale1.9924,30048,2361,813,439May 14 04:36 PM
Saccomano Nicholas APresident and CEOApr 07 '25Sale2.675161,3783,682Apr 08 05:32 PM
Saccomano Nicholas APresident and CEOApr 04 '25Sale3.333581,1914,198Apr 08 05:32 PM
Leverone Jason A.Chief Financial OfficerApr 07 '25Sale2.671,8444,92513,209Apr 08 05:30 PM
Leverone Jason A.Chief Financial OfficerApr 04 '25Sale3.331,2784,25315,053Apr 08 05:30 PM
Last Close
Oct 31  •  04:00PM ET
10.69
Dollar change
+0.23
Percentage change
2.20
%
AARD Aardvark Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.69 Insider Own43.30% Shs Outstand21.69M Perf Week-0.09%
Market Cap231.94M Forward P/E- EPS next Y-3.39 Insider Trans0.38% Shs Float12.30M Perf Month-30.45%
Enterprise Value90.77M PEG- EPS next Q-0.81 Inst Own23.04% Short Float4.55% Perf Quarter-14.48%
Income-36.64M P/S- EPS this Y42.69% Inst Trans1.76% Short Ratio3.56 Perf Half Y-16.87%
Sales0.00M P/B1.69 EPS next Y-14.71% ROA-46.77% Short Interest0.56M Perf YTD-25.30%
Book/sh6.31 P/C1.64 EPS next 5Y12.14% ROE-110.36% 52W High19.58 -45.40% Perf Year-
Cash/sh6.54 P/FCF- EPS past 3/5Y-22.31% - ROIC-26.71% 52W Low4.88 119.06% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.86% 8.25% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM46.68% Oper. Margin- ATR (14)1.00 Perf 10Y-
Dividend Ex-Date- Quick Ratio14.04 Sales Y/Y TTM- Profit Margin- RSI (14)38.67 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio14.04 EPS Q/Q68.88% SMA20-19.93% Beta- Target Price31.43
Payout- Debt/Eq0.00 Sales Q/Q- SMA50-8.32% Rel Volume0.63 Prev Close10.46
Employees22 LT Debt/Eq0.00 EarningsAug 13 AMC SMA200-4.83% Avg Volume157.40K Price10.69
IPOFeb 13, 2025 Option/ShortNo / Yes EPS/Sales Surpr.-10.00% - Trades Volume99,354 Change2.20%
Date Action Analyst Rating Change Price Target Change
Sep-29-25Initiated Stifel Buy $24
Jun-30-25Initiated H.C. Wainwright Buy $40
Mar-10-25Initiated RBC Capital Mkts Outperform $21
Mar-10-25Initiated Morgan Stanley Overweight $29
Mar-10-25Initiated Cantor Fitzgerald Overweight $50
Mar-10-25Initiated BofA Securities Buy $22
Oct-22-25 08:00AM
Oct-17-25 09:27AM
Oct-08-25 08:00AM
Sep-23-25 04:05PM
Sep-22-25 08:01AM
09:22PM Loading…
Sep-10-25 09:22PM
Sep-04-25 08:00AM
Aug-27-25 04:10PM
Aug-13-25 04:10PM
Aug-12-25 08:00AM
Jul-18-25 08:00AM
Jul-15-25 07:30AM
Jul-01-25 05:31PM
Jun-24-25 08:00AM
Jun-03-25 09:55AM
04:10PM Loading…
May-19-25 04:10PM
May-14-25 04:10PM
May-07-25 04:05PM
Mar-31-25 04:10PM
Mar-27-25 04:18PM
Mar-21-25 09:20AM
Mar-14-25 11:25AM
Mar-03-25 02:55PM
Feb-12-25 10:38PM
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee Tien-LiChief Executive OfficerOct 15 '25Option Exercise4.241,2295,2111,544,613Oct 16 06:14 PM
Jones BryanChief Operating OfficerOct 15 '25Option Exercise4.241,2505,3001,250Oct 16 06:12 PM
Lee Tien-LiChief Executive OfficerSep 15 '25Buy9.6610,00096,6241,543,384Sep 16 06:15 AM
VICKERS VENT GLB DEEP-TECH FNDDirectorSep 15 '25Proposed Sale9.0210,36093,413Sep 15 04:05 PM
Lee Tien-LiChief Executive OfficerSep 10 '25Buy7.919,00071,2121,522,384Sep 12 08:28 PM
Lee Tien-LiChief Executive OfficerSep 11 '25Buy7.826,00046,9261,528,384Sep 12 08:28 PM
Lee Tien-LiChief Executive OfficerSep 12 '25Buy8.505,00042,5161,533,384Sep 12 08:28 PM
Sun NelsonChief Financial OfficerSep 09 '25Buy8.076,00048,440105,484Sep 10 05:36 PM
VICKERS VENT GLB DEEP-TECH FNDDirectorSep 02 '25Proposed Sale8.5120,000170,118Sep 02 04:05 PM
Lee Tien-LiChief Executive OfficerAug 28 '25Option Exercise4.2417,20972,9661,513,384Aug 29 04:05 PM
VICKERS VENT GLB DEEP-TECH FNDDirectorAug 28 '25Proposed Sale8.7227,691241,565Aug 28 04:36 PM
Decheng Capital Global Life Sc10% OwnerFeb 14 '25Buy16.001,250,00020,000,0002,958,887Feb 19 05:44 PM
Lee Tien-LiChief Executive OfficerFeb 14 '25Buy16.0016,542264,6721,496,175Feb 19 04:35 PM
Sun NelsonChief Financial OfficerFeb 14 '25Buy16.0010,000160,00099,484Feb 19 04:30 PM
Cormorant Asset Management, LPFormer 10% OwnerFeb 14 '25Buy16.00187,5003,000,000987,689Feb 19 04:02 PM
Last Close
Oct 31  •  04:00PM ET
54.75
Dollar change
+0.28
Percentage change
0.51
%
DRUG Bright Minds Biosciences Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-0.95 Insider Own30.37% Shs Outstand7.08M Perf Week-10.51%
Market Cap387.63M Forward P/E- EPS next Y-5.12 Insider Trans0.00% Shs Float4.93M Perf Month-2.23%
Enterprise Value350.07M PEG- EPS next Q-0.57 Inst Own59.83% Short Float4.69% Perf Quarter54.36%
Income-6.38M P/S- EPS this Y-232.54% Inst Trans0.49% Short Ratio2.33 Perf Half Y70.19%
Sales0.00M P/B10.21 EPS next Y-239.73% ROA-29.62% Short Interest0.23M Perf YTD52.00%
Book/sh5.36 P/C10.29 EPS next 5Y- ROE-30.05% 52W High70.23 -22.04% Perf Year21.61%
Cash/sh5.32 P/FCF- EPS past 3/5Y49.96% -59.48% ROIC-16.77% 52W Low23.17 136.25% Perf 3Y984.16%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.90% 9.94% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-38.86% Oper. Margin- ATR (14)5.05 Perf 10Y-
Dividend Ex-Date- Quick Ratio86.56 Sales Y/Y TTM- Profit Margin- RSI (14)44.84 Recom1.17
Dividend Gr. 3/5Y- - Current Ratio86.56 EPS Q/Q-1581.44% SMA20-9.70% Beta-6.14 Target Price76.10
Payout- Debt/Eq0.00 Sales Q/Q- SMA503.44% Rel Volume1.26 Prev Close54.47
Employees- LT Debt/Eq0.00 EarningsAug 14 BMO SMA20044.65% Avg Volume99.23K Price54.75
IPOMar 22, 2021 Option/ShortNo / Yes EPS/Sales Surpr.6.78% - Trades Volume124,622 Change0.51%
Date Action Analyst Rating Change Price Target Change
Sep-08-25Initiated BTIG Research Buy $72
May-13-25Initiated TD Cowen Buy
May-07-25Initiated Chardan Capital Markets Buy $80
Jan-23-25Initiated Piper Sandler Overweight $93
Jan-10-25Initiated H.C. Wainwright Buy $85
Jan-10-25Initiated Cantor Fitzgerald Overweight
Nov-26-24Initiated Robert W. Baird Outperform $75
Oct-30-25 06:30PM
Oct-15-25 08:50AM
Sep-18-25 09:55AM
Sep-07-25 05:29PM
Sep-04-25 08:30AM
09:55AM Loading…
Sep-02-25 09:55AM
03:50AM
Aug-25-25 08:00AM
May-28-25 08:00AM
May-20-25 08:00AM
May-13-25 08:30AM
May-11-25 03:33PM
May-09-25 11:11AM
Apr-28-25 08:00AM
Apr-16-25 12:09PM
08:00AM Loading…
Mar-04-25 08:00AM
Feb-24-25 06:50AM
Jan-07-25 06:50AM
Nov-21-24 09:00AM
Nov-06-24 06:30AM
Nov-04-24 02:41PM
Oct-21-24 08:30AM
Oct-18-24 06:50AM
Oct-16-24 10:45AM
09:20AM
05:57AM
Oct-15-24 09:09PM
Oct-03-24 09:00AM
Sep-19-24 10:00AM
Sep-12-24 08:00AM
07:30AM Loading…
Aug-12-24 07:30AM
May-20-24 11:53AM
Dec-06-23 05:08PM
Aug-08-23 06:50AM
Jul-20-23 06:50AM
Jul-11-23 06:50AM
Jun-22-23 06:50AM
Apr-19-23 06:50AM
Apr-10-23 06:50AM
Feb-27-23 06:50AM
Feb-17-23 06:50AM
Feb-08-23 04:05PM
Jan-27-23 04:05PM
Jan-09-23 04:05PM
Dec-02-22 07:07PM
Nov-28-22 06:50AM
Nov-23-22 11:35AM
Sep-07-22 06:50AM
Aug-31-22 06:50AM
Aug-30-22 03:35PM
Aug-23-22 09:07PM
Aug-22-22 07:05PM
Aug-18-22 03:34PM
Jun-27-22 06:50AM
May-12-22 06:50AM
May-02-22 06:50AM
Apr-19-22 06:50AM
Mar-14-22 06:50AM
Mar-08-22 07:30AM
Jan-04-22 04:05PM
Dec-15-21 05:13PM
Dec-06-21 06:50AM
Nov-30-21 07:30AM
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cormorant Asset Management, LP10% OwnerNov 04 '24Buy21.70184,3313,999,9831,059,331Nov 06 04:20 PM
Last Close
Oct 31  •  04:00PM ET
7.57
Dollar change
-0.16
Percentage change
-2.07
%
BIOA BioAge Labs Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.24 Insider Own41.29% Shs Outstand35.85M Perf Week-0.39%
Market Cap271.38M Forward P/E- EPS next Y-2.56 Insider Trans0.00% Shs Float21.05M Perf Month28.31%
Enterprise Value-17.17M PEG- EPS next Q-0.58 Inst Own33.97% Short Float3.29% Perf Quarter71.27%
Income-79.03M P/S70.31 EPS this Y66.80% Inst Trans3.14% Short Ratio2.29 Perf Half Y80.67%
Sales3.86M P/B0.92 EPS next Y-16.25% ROA-32.48% Short Interest0.69M Perf YTD30.74%
Book/sh8.22 P/C0.91 EPS next 5Y25.29% ROE-35.88% 52W High24.66 -69.30% Perf Year-69.90%
Cash/sh8.29 P/FCF- EPS past 3/5Y-30.62% - ROIC-26.58% 52W Low2.88 162.85% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin95.34% Volatility6.22% 6.16% Perf 5Y-
Dividend TTM- EV/Sales-4.45 EPS Y/Y TTM- Oper. Margin-2364.20% ATR (14)0.49 Perf 10Y-
Dividend Ex-Date- Quick Ratio13.21 Sales Y/Y TTM- Profit Margin-2045.74% RSI (14)68.24 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio13.21 EPS Q/Q-51.32% SMA2020.69% Beta1.96 Target Price9.67
Payout- Debt/Eq0.03 Sales Q/Q- SMA5036.80% Rel Volume0.92 Prev Close7.73
Employees64 LT Debt/Eq0.01 EarningsAug 06 AMC SMA20063.96% Avg Volume303.19K Price7.57
IPOSep 26, 2024 Option/ShortYes / Yes EPS/Sales Surpr.-24.56% - Trades Volume278,091 Change-2.07%
Date Action Analyst Rating Change Price Target Change
Oct-22-25Upgrade Citigroup Neutral → Buy $10
Feb-28-25Initiated William Blair Mkt Perform
Dec-10-24Downgrade Morgan Stanley Overweight → Underweight $40 → $5
Dec-09-24Downgrade Jefferies Buy → Hold $42 → $7
Dec-09-24Downgrade Citigroup Buy → Neutral $45 → $7
Oct-21-24Initiated Morgan Stanley Overweight $40
Oct-21-24Initiated Jefferies Buy $42
Oct-21-24Initiated Citigroup Buy $45
Oct-29-25 06:15AM
Oct-26-25 06:33PM
Oct-23-25 07:36AM
Aug-20-25 04:30PM
Aug-18-25 07:36AM
09:00AM Loading…
Aug-15-25 09:00AM
Aug-06-25 04:30PM
Jul-29-25 10:23AM
Jun-21-25 06:00PM
Jun-17-25 09:00AM
Jun-03-25 09:00AM
May-30-25 09:05AM
May-29-25 11:18PM
09:00AM
May-27-25 04:30PM
04:30PM Loading…
May-06-25 04:30PM
Apr-21-25 01:02PM
Mar-22-25 11:00AM
Mar-20-25 04:30PM
Mar-17-25 01:54PM
Mar-04-25 05:07AM
Feb-20-25 04:30PM
10:36AM
Feb-16-25 07:18AM
Feb-14-25 05:45AM
Feb-13-25 08:42AM
Feb-07-25 05:45AM
Jan-30-25 09:01AM
Jan-29-25 05:39AM
Jan-28-25 07:27PM
09:00AM Loading…
09:00AM
Jan-24-25 05:45AM
Jan-22-25 03:00AM
Jan-21-25 05:45AM
Jan-18-25 03:07AM
Jan-06-25 09:00PM
Jan-03-25 12:51PM
Jan-02-25 09:35AM
Jan-01-25 05:00AM
Dec-27-24 11:32AM
09:18AM
Dec-26-24 07:23AM
Dec-25-24 07:04AM
Dec-23-24 10:19AM
Dec-19-24 01:15PM
05:46AM
Dec-18-24 09:00AM
Dec-16-24 04:20PM
03:00AM
Dec-13-24 10:31AM
Dec-12-24 06:34PM
Dec-09-24 07:51PM
09:28AM
07:41AM
Dec-07-24 06:34AM
Dec-06-24 04:35PM
Dec-05-24 04:30PM
Dec-04-24 04:47PM
Nov-21-24 04:30PM
Nov-12-24 11:01PM
Nov-07-24 04:30PM
Nov-04-24 09:00AM
Oct-24-24 09:00AM
Oct-21-24 10:53AM
Oct-17-24 09:45AM
Oct-12-24 02:31PM
Oct-07-24 09:10PM
Oct-05-24 07:15AM
Oct-03-24 09:05AM
Oct-01-24 04:30PM
Sep-26-24 04:08PM
02:36PM
08:25AM
Sep-25-24 08:00PM
04:13PM
11:27AM
Jan-01-01 12:00AM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Last Close
Oct 31  •  04:00PM ET
12.15
Dollar change
-4.29
Percentage change
-26.09
%
CRBP Corbus Pharmaceuticals Holdings Inc daily Stock Chart
Index- P/E- EPS (ttm)-4.76 Insider Own11.84% Shs Outstand12.25M Perf Week-28.02%
Market Cap148.90M Forward P/E- EPS next Y-5.15 Insider Trans-3.49% Shs Float10.80M Perf Month-6.61%
Enterprise Value34.48M PEG- EPS next Q-1.66 Inst Own65.16% Short Float9.13% Perf Quarter30.09%
Income-57.95M P/S- EPS this Y-68.54% Inst Trans-9.02% Short Ratio4.71 Perf Half Y55.97%
Sales0.00M P/B1.34 EPS next Y16.89% ROA-41.83% Short Interest0.99M Perf YTD2.97%
Book/sh9.06 P/C1.27 EPS next 5Y-18.26% ROE-49.00% 52W High20.77 -41.50% Perf Year-25.00%
Cash/sh9.54 P/FCF- EPS past 3/5Y30.83% 35.71% ROIC-51.86% 52W Low4.64 161.85% Perf 3Y209.87%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.53% 10.40% Perf 5Y-57.97%
Dividend TTM- EV/Sales- EPS Y/Y TTM18.15% Oper. Margin- ATR (14)1.67 Perf 10Y-76.32%
Dividend Ex-Date- Quick Ratio9.21 Sales Y/Y TTM- Profit Margin- RSI (14)35.01 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.21 EPS Q/Q-59.54% SMA20-26.69% Beta2.72 Target Price41.80
Payout- Debt/Eq0.02 Sales Q/Q- SMA50-7.60% Rel Volume13.82 Prev Close16.44
Employees28 LT Debt/Eq0.01 EarningsAug 05 BMO SMA20031.27% Avg Volume209.57K Price12.15
IPOOct 27, 2014 Option/ShortYes / Yes EPS/Sales Surpr.3.72% - Trades Volume2,896,491 Change-26.09%
Date Action Analyst Rating Change Price Target Change
Jul-30-25Resumed B. Riley Securities Buy $28
Feb-28-25Initiated William Blair Outperform
Dec-02-24Initiated Piper Sandler Overweight
Jul-30-24Initiated Wedbush Outperform $85
Jul-22-24Resumed H.C. Wainwright Buy $80
Jun-26-24Initiated B. Riley Securities Buy $85
Jun-03-24Reiterated Oppenheimer Outperform $60 → $80
May-13-24Initiated RBC Capital Mkts Outperform $77
Mar-06-24Upgrade Jefferies Hold → Buy $4 → $46
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Today 02:40AM
Oct-30-25 04:31PM
Oct-18-25 03:00AM
Oct-14-25 08:00AM
Oct-07-25 08:00AM
08:00AM Loading…
Sep-22-25 08:00AM
Sep-16-25 08:00AM
Aug-08-25 10:15AM
Aug-05-25 08:11AM
08:00AM
Jul-30-25 08:00AM
Jun-30-25 08:00AM
Jun-25-25 08:00AM
Jun-24-25 04:05PM
May-23-25 11:13AM
08:00AM Loading…
May-22-25 08:00AM
May-19-25 08:00AM
May-16-25 07:48AM
May-08-25 08:00AM
07:20AM
May-06-25 08:08AM
08:00AM
Apr-29-25 08:14AM
Apr-18-25 09:55AM
Mar-28-25 08:00AM
Mar-20-25 09:35AM
Mar-19-25 09:35AM
Mar-13-25 12:00PM
Mar-11-25 08:17AM
08:00AM
08:00AM Loading…
Feb-25-25 08:00AM
Feb-14-25 01:17PM
07:30AM
Feb-11-25 07:30AM
Jan-28-25 08:00AM
Jan-08-25 08:00AM
Jan-06-25 08:00AM
Dec-09-24 07:00AM
Dec-04-24 12:31PM
Dec-03-24 07:00AM
Nov-26-24 06:54AM
Nov-21-24 08:00AM
Nov-12-24 08:00AM
Nov-07-24 07:28AM
07:00AM
Nov-04-24 04:10PM
07:00AM
Oct-29-24 08:00AM
Oct-16-24 08:00AM
Oct-15-24 07:02PM
Oct-11-24 07:02PM
Oct-03-24 05:07AM
Sep-26-24 08:00AM
Sep-24-24 09:41PM
Sep-20-24 03:18PM
Sep-12-24 07:59AM
Sep-05-24 08:00AM
Sep-04-24 07:29PM
Sep-02-24 05:22PM
Aug-27-24 08:03PM
Aug-26-24 09:55AM
Aug-21-24 05:00AM
Aug-20-24 08:00AM
Aug-09-24 12:00PM
09:55AM
Aug-06-24 08:08AM
08:00AM
Jul-30-24 08:50AM
Jul-01-24 11:13AM
Jun-30-24 10:13AM
Jun-01-24 10:00AM
May-30-24 08:00AM
May-23-24 05:05PM
May-17-24 04:12PM
May-09-24 08:00AM
May-07-24 01:52PM
08:17AM
08:00AM
May-06-24 02:06PM
May-01-24 08:00AM
Apr-24-24 04:05PM
Apr-19-24 02:30PM
Apr-16-24 08:50AM
Apr-12-24 06:40AM
Apr-02-24 08:00AM
Mar-15-24 08:50AM
Mar-14-24 09:38AM
Mar-12-24 08:21AM
08:00AM
Mar-06-24 08:00AM
Feb-28-24 08:00AM
Feb-06-24 09:50AM
Feb-02-24 04:01PM
Jan-31-24 09:19AM
Jan-30-24 06:55PM
Jan-29-24 06:57AM
Jan-26-24 07:30AM
Jan-23-24 08:00AM
Jan-09-24 08:00AM
Dec-18-23 08:00AM
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cohen YuvalChief Executive OfficerOct 24 '25Option Exercise4.2618,66079,492156,847Oct 27 04:23 PM
Cohen YuvalChief Executive OfficerOct 27 '25Option Exercise4.268,97338,225147,160Oct 27 04:23 PM
Cohen YuvalChief Executive OfficerOct 24 '25Sale17.0118,660317,407138,187Oct 27 04:23 PM
Cohen YuvalChief Executive OfficerOct 27 '25Sale17.148,973153,797138,187Oct 27 04:23 PM
Moran Sean F.Chief Financial OfficerOct 24 '25Option Exercise4.2612,98155,29986,294Oct 27 04:22 PM
Moran Sean F.Chief Financial OfficerOct 24 '25Sale17.0212,981220,93773,313Oct 27 04:22 PM
Cohen YuvalOfficerOct 24 '25Proposed Sale17.0127,633469,977Oct 24 04:18 PM
Moran Sean F.OfficerOct 24 '25Proposed Sale17.0212,981220,922Oct 24 04:14 PM
Altmeyer AnneDirectorOct 20 '25Option Exercise4.801,0605,0887,251Oct 21 04:54 PM
Altmeyer AnneDirectorOct 20 '25Sale20.501,06021,7306,191Oct 21 04:54 PM
Jenkins John KennethDirectorMay 30 '25Sale7.352,78320,46533Jun 02 04:30 PM
Altmeyer AnneDirectorMay 30 '25Sale7.251,39210,0961,391Jun 02 04:30 PM
Smethurst DominicChief Medical OfficerMar 06 '25Sale6.786,39343,33070,807Mar 07 04:30 PM
Smethurst DominicOfficerMar 06 '25Proposed Sale6.846,39343,728Mar 06 04:03 PM
Moran Sean F.Chief Financial OfficerFeb 14 '25Sale8.762,79224,44673,313Feb 18 05:40 PM
Cohen YuvalChief Executive OfficerFeb 14 '25Sale8.767,13462,465138,187Feb 18 05:40 PM
Moran Sean F.OfficerFeb 14 '25Proposed Sale9.482,79226,468Feb 14 04:18 PM
Cohen YuvalOfficerFeb 14 '25Proposed Sale9.487,13467,630Feb 14 04:16 PM
Last Close
Oct 31  •  04:00PM ET
13.09
Dollar change
+0.88
Percentage change
7.21
%
EYPT EyePoint Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-2.68 Insider Own12.25% Shs Outstand68.89M Perf Week9.27%
Market Cap902.26M Forward P/E- EPS next Y-3.02 Insider Trans0.24% Shs Float60.48M Perf Month-3.04%
Enterprise Value668.35M PEG- EPS next Q-0.77 Inst Own90.04% Short Float13.43% Perf Quarter30.12%
Income-175.38M P/S17.38 EPS this Y-29.54% Inst Trans-7.04% Short Ratio7.78 Perf Half Y79.32%
Sales51.90M P/B3.67 EPS next Y-0.43% ROA-56.09% Short Interest8.13M Perf YTD75.70%
Book/sh3.57 P/C3.53 EPS next 5Y-3.62% ROE-73.95% 52W High14.91 -12.21% Perf Year13.43%
Cash/sh3.71 P/FCF- EPS past 3/5Y-4.60% 15.65% ROIC-65.48% 52W Low3.91 234.78% Perf 3Y127.26%
Dividend Est.- EV/EBITDA- Sales past 3/5Y5.42% 16.27% Gross Margin94.10% Volatility6.30% 6.44% Perf 5Y218.88%
Dividend TTM- EV/Sales12.88 EPS Y/Y TTM-49.11% Oper. Margin-364.27% ATR (14)0.78 Perf 10Y-66.18%
Dividend Ex-Date- Quick Ratio7.91 Sales Y/Y TTM2.99% Profit Margin-337.93% RSI (14)55.83 Recom1.08
Dividend Gr. 3/5Y- - Current Ratio8.00 EPS Q/Q-46.67% SMA204.78% Beta1.87 Target Price34.83
Payout- Debt/Eq0.09 Sales Q/Q-43.73% SMA501.94% Rel Volume1.45 Prev Close12.21
Employees165 LT Debt/Eq0.09 EarningsNov 05 BMO SMA20045.40% Avg Volume1.04M Price13.09
IPOJan 27, 2005 Option/ShortYes / Yes EPS/Sales Surpr.-3.32% -19.81% Trades Volume1,513,650 Change7.21%
Date Action Analyst Rating Change Price Target Change
Jun-17-25Initiated RBC Capital Mkts Outperform $28
Jan-07-25Initiated Citigroup Buy $33
Oct-16-24Initiated Scotiabank Sector Outperform
Aug-28-24Initiated Jefferies Buy $15
Jan-22-24Initiated JP Morgan Overweight $35
Nov-02-23Initiated Mizuho Buy $20
Apr-21-23Initiated Robert W. Baird Outperform $33
Jul-07-22Initiated Chardan Capital Markets Buy $21
Mar-01-21Initiated Cowen Outperform $25
Jan-28-21Initiated Cantor Fitzgerald Overweight $22
Oct-29-25 07:00AM
Oct-16-25 07:00AM
Oct-14-25 10:43PM
04:35PM
04:01PM
09:29AM Loading…
Sep-25-25 09:29AM
Sep-23-25 01:13PM
Sep-16-25 07:00AM
Aug-26-25 07:00AM
Aug-18-25 04:01PM
Aug-06-25 08:30AM
07:30AM
07:26AM
07:00AM
Aug-05-25 10:08AM
06:00PM Loading…
Jul-30-25 06:00PM
07:00AM
05:57AM
Jul-29-25 07:00AM
Jul-16-25 07:00AM
Jun-16-25 07:00AM
Jun-06-25 11:54AM
May-28-25 04:01PM
May-27-25 07:00AM
May-16-25 07:00AM
May-13-25 07:00AM
May-07-25 02:49PM
02:49PM
09:30AM
08:25AM
07:22AM Loading…
07:22AM
07:00AM
Apr-30-25 07:00AM
Apr-16-25 07:00AM
Mar-27-25 07:00AM
Mar-17-25 07:00AM
Mar-06-25 02:14AM
02:06AM
Mar-05-25 09:30AM
08:25AM
07:34AM
07:00AM
Mar-04-25 07:17AM
07:00AM
Feb-26-25 07:00AM
Feb-25-25 07:00AM
Feb-17-25 07:00AM
Feb-05-25 07:00AM
Jan-30-25 07:00AM
Jan-16-25 07:00AM
Jan-13-25 07:00AM
Jan-08-25 07:00AM
Dec-17-24 07:25AM
07:00AM
Dec-16-24 07:00AM
Dec-05-24 07:06AM
Dec-04-24 07:00AM
Nov-18-24 07:00AM
Nov-13-24 09:55AM
Nov-12-24 06:45AM
Nov-07-24 08:35AM
07:37AM
07:00AM
Nov-04-24 07:00AM
Oct-31-24 04:00PM
Oct-29-24 09:47PM
04:49AM
Oct-28-24 05:14PM
12:16PM
07:00AM
Oct-24-24 07:00AM
Oct-23-24 09:20AM
Oct-16-24 07:00AM
Sep-16-24 07:00AM
Sep-04-24 07:00AM
Aug-27-24 07:00AM
Aug-16-24 07:00AM
Aug-08-24 07:00AM
Aug-07-24 08:15AM
07:09AM
07:00AM
Jul-16-24 07:00AM
Jul-15-24 08:00AM
Jun-26-24 08:00AM
08:00AM
Jun-18-24 07:00AM
Jun-17-24 07:00AM
Jun-05-24 07:00AM
02:35AM
May-17-24 02:34AM
May-16-24 07:00AM
May-10-24 02:34PM
May-08-24 01:54PM
10:48AM
07:23AM
07:00AM
May-07-24 09:32AM
May-06-24 11:00AM
08:42AM
07:00AM
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zaderej Karen L.DirectorJul 11 '25Option Exercise0.002,000038,500Jul 11 04:07 PM
Lurker NancyDirectorJul 10 '25Option Exercise0.0011,1110216,547Jul 11 04:06 PM
Duker Jay S.President and CEOJul 10 '25Option Exercise0.0016,667017,653Jul 11 04:06 PM
Elston GeorgeChief Financial OfficerMay 25 '25Option Exercise0.007,500083,050May 27 04:08 PM
Zaderej Karen L.DirectorMay 19 '25Buy5.995,00029,95036,500May 19 04:06 PM
Zaderej Karen L.DirectorMay 16 '25Buy5.815,00029,05031,500May 19 04:06 PM
Zaderej Karen L.DirectorMay 15 '25Buy5.475,00027,35026,500May 15 04:06 PM
Zaderej Karen L.DirectorMay 14 '25Buy5.425,00027,10021,500May 15 04:06 PM
Elston GeorgeChief Financial OfficerFeb 09 '25Option Exercise0.005,834075,550Feb 11 06:19 PM
Lurker NancyDirectorFeb 09 '25Option Exercise0.0020,0000205,436Feb 11 06:19 PM
Duker Jay S.President and CEOFeb 09 '25Option Exercise0.007,000079,706Feb 11 06:19 PM
Elston GeorgeChief Financial OfficerJan 06 '25Option Exercise0.0015,285073,374Jan 07 04:04 PM
Elston GeorgeChief Financial OfficerJan 05 '25Option Exercise0.0015,000063,356Jan 07 04:04 PM
Lurker NancyDirectorJan 06 '25Option Exercise0.0075,1340185,436Jan 07 04:04 PM
Lurker NancyDirectorJan 05 '25Option Exercise0.0012,6670110,302Jan 07 04:04 PM
Landis John B.DirectorJan 05 '25Option Exercise0.0010,000021,400Jan 07 04:04 PM
Duker Jay S.President and CEOJan 06 '25Option Exercise0.0020,794078,814Jan 07 04:03 PM
Duker Jay S.President and CEOJan 05 '25Option Exercise0.0030,000068,027Jan 07 04:03 PM
Last Close
Oct 31  •  04:00PM ET
6.87
Dollar change
+0.46
Percentage change
7.18
%
IMRX Immuneering Corp daily Stock Chart
Index- P/E- EPS (ttm)-1.90 Insider Own21.66% Shs Outstand60.53M Perf Week13.74%
Market Cap415.84M Forward P/E- EPS next Y-1.85 Insider Trans1.15% Shs Float47.42M Perf Month5.21%
Enterprise Value393.48M PEG- EPS next Q-0.39 Inst Own13.67% Short Float16.22% Perf Quarter100.29%
Income-62.13M P/S- EPS this Y22.30% Inst Trans34.62% Short Ratio4.31 Perf Half Y454.03%
Sales0.00M P/B8.54 EPS next Y-16.93% ROA-106.07% Short Interest7.69M Perf YTD212.27%
Book/sh0.80 P/C15.78 EPS next 5Y2.00% ROE-130.47% 52W High10.08 -31.85% Perf Year246.97%
Cash/sh0.44 P/FCF- EPS past 3/5Y-16.91% -46.45% ROIC-190.76% 52W Low1.10 524.55% Perf 3Y-48.88%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.02% 8.45% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM0.66% Oper. Margin- ATR (14)0.59 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.70 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)57.03 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.70 EPS Q/Q15.52% SMA2013.14% Beta0.46 Target Price16.67
Payout- Debt/Eq0.14 Sales Q/Q- SMA503.23% Rel Volume0.97 Prev Close6.41
Employees66 LT Debt/Eq0.13 EarningsAug 13 AMC SMA200105.52% Avg Volume1.78M Price6.87
IPOJul 30, 2021 Option/ShortYes / Yes EPS/Sales Surpr.0.07% - Trades Volume1,735,001 Change7.18%
Date Action Analyst Rating Change Price Target Change
TodayInitiated Leerink Partners Outperform $15
Dec-13-24Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-15-24Reiterated Needham Buy $20 → $15
Mar-15-24Downgrade TD Cowen Outperform → Market Perform
Mar-15-24Downgrade Jefferies Buy → Hold $16 → $3
Dec-01-23Initiated Needham Buy $20
Jun-26-23Resumed Oppenheimer Outperform $25
Apr-19-23Upgrade Morgan Stanley Underweight → Equal-Weight $5 → $14
Apr-19-23Upgrade Mizuho Neutral → Buy $10 → $20
Mar-30-23Initiated Mizuho Neutral $10
Today 09:33AM
Sep-30-25 11:42AM
Sep-26-25 04:01PM
Sep-25-25 12:08AM
Sep-24-25 04:05PM
04:01PM Loading…
04:01PM
Sep-16-25 07:00AM
Sep-10-25 07:00AM
Aug-26-25 04:05PM
11:17AM
Aug-25-25 08:00AM
Aug-21-25 08:00AM
Aug-13-25 04:05PM
Jul-10-25 09:20AM
Jul-09-25 08:00AM
04:00AM Loading…
Jul-08-25 04:00AM
Jun-20-25 09:21AM
Jun-17-25 06:00AM
Jun-16-25 08:00AM
May-29-25 08:00AM
May-05-25 04:05PM
Apr-02-25 08:00AM
Mar-21-25 04:30PM
Mar-20-25 04:05PM
07:12AM
07:00AM
Feb-06-25 07:00AM
Feb-03-25 04:05PM
Jan-13-25 08:00AM
Jan-07-25 09:28AM
07:00AM Loading…
07:00AM
Dec-23-24 10:49AM
Dec-19-24 08:00AM
Dec-17-24 08:00AM
Dec-13-24 02:10PM
Dec-12-24 08:00AM
Nov-27-24 08:00AM
Nov-13-24 04:05PM
Oct-15-24 08:00AM
Sep-13-24 08:14AM
Sep-12-24 04:05PM
Aug-29-24 08:00AM
Aug-06-24 04:05PM
Jul-31-24 04:05PM
May-29-24 04:05PM
May-17-24 12:50PM
May-07-24 10:55PM
04:05PM
May-06-24 04:30PM
Apr-09-24 12:00PM
Apr-03-24 04:05PM
Mar-27-24 08:00AM
Mar-18-24 11:02AM
Mar-14-24 07:00AM
Mar-12-24 08:00AM
Mar-11-24 08:00AM
Mar-06-24 08:00AM
Mar-05-24 05:00PM
Mar-04-24 08:00AM
Mar-03-24 07:01PM
Mar-01-24 08:00AM
Feb-20-24 08:00AM
Feb-14-24 03:45PM
Feb-01-24 08:00AM
Dec-12-23 08:00AM
Nov-20-23 04:05PM
Nov-09-23 04:05PM
Oct-12-23 04:05PM
Oct-04-23 04:05PM
Sep-06-23 08:00AM
Aug-03-23 04:05PM
Aug-02-23 06:09AM
Jul-05-23 09:55AM
Jun-05-23 08:00AM
May-30-23 08:00AM
May-04-23 07:25PM
04:05PM
Apr-18-23 09:24AM
09:00AM
04:20AM
Apr-12-23 04:05PM
Apr-11-23 03:56AM
Apr-05-23 08:00AM
Mar-28-23 08:00AM
Mar-27-23 09:55AM
Mar-24-23 01:25PM
Mar-23-23 06:18AM
Mar-14-23 04:30PM
Mar-09-23 09:55AM
Mar-08-23 07:14AM
Mar-06-23 05:45PM
04:05PM
Mar-05-23 06:30PM
Feb-28-23 08:00AM
Feb-27-23 08:00AM
Feb-05-23 07:18AM
Jan-31-23 06:50AM
Nov-28-22 06:50AM
Nov-16-22 06:35AM
Nov-10-22 10:15AM
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Feinberg PeterDirectorOct 03 '25Buy6.677,50050,025156,766Oct 07 08:56 AM
Morales MalloryChief Accounting OfficerOct 01 '25Buy6.393001,91727,533Oct 02 09:02 AM
Neufeld Leah RCHIEF PEOPLE OFFICEROct 01 '25Buy6.388005,10323,344Oct 02 08:57 AM
Bookman MichaelCHIEF LEGAL OFFICER, SECRETARYOct 01 '25Buy6.831,0206,9664,870Oct 02 08:52 AM
Feinberg PeterDirectorSep 30 '25Buy7.037,50052,730149,266Oct 01 08:59 AM
Feinberg PeterDirectorSep 29 '25Buy7.185,00035,900141,766Sep 30 09:00 AM
BERMAN ANN EDirectorSep 23 '25Proposed Sale9.7214,000136,080Sep 23 08:48 AM
HAUSMAN DIANADirectorJul 02 '25Buy3.623,00010,8743,000Jul 07 08:59 AM
HAUSMAN DIANADirectorJul 02 '25Buy3.602,5008,9892,500Jul 07 08:59 AM
Neufeld Leah RCHIEF PEOPLE OFFICERJul 02 '25Buy3.577002,49910,729Jul 07 08:52 AM
Zeskind Benjamin J.PRESIDENT AND CEOJul 02 '25Buy3.537,01524,7922,312,852Jul 03 09:12 AM
Zeskind Benjamin J.PRESIDENT AND CEOJul 01 '25Buy3.382,98510,0872,305,837Jul 03 09:12 AM
Schall Thomas J.DirectorJun 27 '25Buy3.669,50034,78852,885Jun 30 09:09 AM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJun 20 '25Buy2.707,41520,020353,311Jun 24 09:01 AM
Hall Brett MatthewCHIEF SCIENTIFIC OFFICERJun 23 '25Buy2.436,00714,596359,318Jun 24 09:01 AM
Brakewood Harold EugeneChief Business OfficerJun 20 '25Buy2.531,9004,8045,800Jun 24 08:52 AM
Feinberg PeterDirectorJun 18 '25Buy2.5325,00063,188136,766Jun 23 09:09 AM
Zeskind Benjamin J.PRESIDENT AND CEOJun 18 '25Buy2.3921,00050,1442,302,852Jun 20 09:09 AM
Schall Thomas J.DirectorJun 17 '25Buy2.2140,48589,27843,385Jun 18 09:11 AM